Ibaraki, Japan

Akira Uemura


Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 1993

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Akira Uemura

Introduction: Akira Uemura, an esteemed inventor based in Ibaraki, Japan, has made significant strides in the field of pharmaceutical innovations. With a focus on improving drug delivery systems, Uemura's work has contributed to the enhancement of patient care through more effective medication administration.

Latest Patents: Uemura holds a notable patent for a sustained-release preparation of a basic medical agent hydrochloride. This innovative preparation involves coating granules containing both the basic medical agent hydrochloride, such as allotinolol hydrochloride, and a polyanion in a way that allows for controlled release. This method ensures that the agent can be administered orally without being impacted by the varying physiological factors of the gastrointestinal tract, allowing for consistent and reliable medication delivery.

Career Highlights: Currently, Uemura is associated with Sumitomo Pharmaceuticals Company Limited, where she has honed her expertise in pharmaceutical research and development. Her commitment to advancing healthcare solutions has been recognized in the industry through her valuable contributions.

Collaborations: Uemura has worked alongside talented professionals, including Fumio Samizo and Tetsuo Noguchi. Together, they have collaborated on various projects aimed at innovative drug formulations, enhancing the efficiency and efficacy of therapeutic agents.

Conclusion: Akira Uemura's contributions to the pharmaceutical field, particularly through her innovative patent, exemplify the importance of research and development in improving medication administration. Her partnership with esteemed colleagues further illustrates the collaborative nature of innovation, ultimately leading to advancements that benefit patients globally.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…